- Home
- SUUN vs KOD Comparison
SUUN vs KOD Comparison
Compare SUUN & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUUN
- KOD
- Stock Information
- Founded
- SUUN 2013
- KOD 2009
- Country
- SUUN Canada
- KOD United States
- Employees
- SUUN N/A
- KOD N/A
- Industry
- SUUN
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SUUN
- KOD Health Care
- Exchange
- SUUN Nasdaq
- KOD Nasdaq
- Market Cap
- SUUN 75.1M
- KOD 115.0M
- IPO Year
- SUUN N/A
- KOD 2018
- Fundamental
- Price
- SUUN $1.99
- KOD $3.90
- Analyst Decision
- SUUN Strong Buy
- KOD Hold
- Analyst Count
- SUUN 1
- KOD 3
- Target Price
- SUUN $6.00
- KOD $9.00
- AVG Volume (30 Days)
- SUUN 134.5K
- KOD 469.8K
- Earning Date
- SUUN 05-19-2025
- KOD 05-19-2025
- Dividend Yield
- SUUN N/A
- KOD N/A
- EPS Growth
- SUUN N/A
- KOD N/A
- EPS
- SUUN N/A
- KOD N/A
- Revenue
- SUUN $36,247,013.00
- KOD N/A
- Revenue This Year
- SUUN $15.42
- KOD N/A
- Revenue Next Year
- SUUN $62.53
- KOD N/A
- P/E Ratio
- SUUN N/A
- KOD N/A
- Revenue Growth
- SUUN 43.76
- KOD N/A
- 52 Week Low
- SUUN $1.95
- KOD $1.92
- 52 Week High
- SUUN $6.87
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- SUUN 34.40
- KOD 55.59
- Support Level
- SUUN $1.96
- KOD $3.66
- Resistance Level
- SUUN $2.36
- KOD $4.20
- Average True Range (ATR)
- SUUN 0.15
- KOD 0.47
- MACD
- SUUN 0.03
- KOD 0.02
- Stochastic Oscillator
- SUUN 22.50
- KOD 40.98
About SUUN SolarBank Corporation Common Stock
SolarBank Corp is an independent renewable and clean energy project developer and asset operator based in Canada and the United States. It is engaged in the development and operation of solar photovoltaic power generation projects in the province of Ontario and the state of New York. The company operates in two principal geographical areas - Canada and United States with a substantial portion of its overall revenue being generated from United States.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.